US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...
GlobalData on MSN2d
Abcuro secures $200m as it eyes approval for rare muscle disease drugThe funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...
The following is a summary of “Validity of diagnosis codes to identify a dermatomyositis cohort from electronic health records,” published in the January 2025 issue of Dermatology by Silberzweig et al ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Cyngn Inc. announced that all outstanding Series B cashless warrants have been fully exercised. These warrants were originally issued in connection with a public offering that closed on December 23, ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Hosted on MSN3d
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific ConferencesPHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its ...
Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...
We expect modern medicine to be able to make sense of our health difficulties. What then, when it fails to do so for people ...
Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback